ORPHA:90033
Autoimmune hemolytic anemia, warm type
Also known as: Warm AIHA · wAHA · wAIHA
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Clinical definition (Orphanet)
Warm autoimmune hemolytic anemia is the most common form of autoimmune hemolytic anemia defined by the presence of warm autoantibodies against red blood cells (autoantibodies that are active at temperatures between 37-40°C).
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Is anyone studying this?
1,116
1,116 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=183) is 38.
1,116 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 38 (publications denominator n=183).
874 in the last 10 years · medium confidence · 94.3th percentile (publications denominator)
Is a treatment being tested?
25
trials for this specific condition
25 interventional trials matched this specific condition name; 7 currently recruiting in our sample. 47 trials are registered for autoimmune hemolytic anemia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 26 July 2026
47
trials for autoimmune hemolytic anemia, the broader category this belongs to
Trials registered for a broader category may or may not enrol people with this specific subtype — eligibility criteria vary, and the trial record often doesn't say. Worth raising with a clinician. How we count trials.
25 interventional trials — more than 59.2% of diseases in the trials denominator have none at all (151 of 255; this disease is at the 92.7th percentile).
medium confidence · 92.7th percentile (trials denominator)
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Who's working on it?
989
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Fattizzo B16 papers · 2026
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, SC Ematologia, Milan, Italy.
Papers in Europe PMC - 02Barcellini W15 papers · 2026
Department of Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Papers in Europe PMC - 03Murakhovskaya I9 papers · 2026
Department of Hematology and Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA.
Papers in Europe PMC - 04Branch DR5 papers · 2024
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Papers in Europe PMC - 05
- 06Yang C5 papers · 2026
Department of Transfusion, Zhongshan Hospital, Fudan University, Shanghai, China.
Papers in Europe PMC - 07Chen M4 papers · 2026
Department of Hematology, Peking Union Medical College Hospital and Chinese Academy of Medical Sciences, Beijing, China.
Papers in Europe PMC - 08Crivera C4 papers · 2025
Janssen Global Services, LLC, Horsham, PA, United States
Papers in Europe PMC - 09Michel M4 papers · 2024
Department of Internal Medicine, National Referral Center for Adult Immune Cytopenias Henri Mondor University Hospital, Service de Medecine Interne, CHU Hopital Henri-Mondor, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, 51 Av du Mal de Lattre de Tassigny, 94010 Creteil Cedex, France. Electronic address: marc.michel2@aphp.fr.
Papers in Europe PMC - 10Mitrović M4 papers · 2023
Clinic of Hematology, University Clinical Center of Serbia, Belgrade, Serbia.
Papers in Europe PMC
Recruiting interventional trials
Trials testing a treatment from the matched ClinicalTrials.gov set
25 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07083960·OM336 in Autoimmune Cytopenias
- NCT07039422·Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
- NCT05925023·Sirolimus in the Treatment of Refractory/Relapsed wAIHA
- NCT07530380·UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
- NCT07086976·A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
- NCT07549698·Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
- NCT06847607·A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored below but are not added to the query string.
"Autoimmune hemolytic anemia, warm type" OR "Warm AIHA" OR "wAIHA" OR "Warm Autoimmune Hemolytic Anemia"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Autoimmune hemolytic anemia, warm type" OR "Warm AIHA" OR "wAIHA" OR "Warm Autoimmune Hemolytic Anemia" OR "autoimmune disorder of blood"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 25 interventional · 1 observational · 1 expanded access. Only interventional studies enter the trial headline.
Cross-references (from Mondo): UMLS:C0272118 NCIT:C162611
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: wAHA
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus